浙江海正药业股份有限公司关于替格瑞洛原料药获得CEP证书的公告

Group 1 - The company, Zhejiang Haizheng Pharmaceutical Co., Ltd., has received the Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor from the European Directorate for the Quality of Medicines & HealthCare (EDQM) [1][2] - The CEP certificate indicates that the quality of Ticagrelor is recognized and approved for entry into the European Union and other markets that acknowledge the CEP certification, which positively impacts the company's international market expansion [2] - The global sales volume of Ticagrelor active pharmaceutical ingredient is projected to be approximately 171,705.29 kilograms for 2024, with about 143,714.60 kilograms sold from January to September 2025 [1]